This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

An Exploratory Clinical Trial Evaluating LX109 Gene Therapy in Patients With nAMD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT06022744
Recruitment Status : Not yet recruiting
First Posted : September 5, 2023
Last Update Posted : September 5, 2023
Information provided by (Responsible Party):
Xiaodong Sun, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Brief Summary:
To evaluate the safety and tolerability of intravitreal injection of LX109 in patients with nAMD.

Condition or disease Intervention/treatment Phase
To Evaluate the Safety and Tolerability of Intravitreal Injection of LX109 in Patients With nAMD Drug: LX109 Not Applicable

Detailed Description:
In this study, 9 to 12 participants were enrolled in an open monocular, single dose escalation study design. Two dose groups were set up: low dose group (7×109 VG/ eye, 0.05ml) and high dose group (3.5×1010 VG/ eye, 0.05ml). Among them, 3 to 6 subjects were enrolled in low-dose group and 6 subjects were enrolled in high-dose group.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Exploratory Clinical Trial Evaluating LX109 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Estimated Study Start Date : September 1, 2023
Estimated Primary Completion Date : September 30, 2025
Estimated Study Completion Date : September 30, 2027

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: LX109 Drug: LX109
LX109 gene injection Specification: 0.2ml/bottle, 1.4×1012VG/ml Administration route: intravitreal injection, injection volume 0.05ml/eye

Primary Outcome Measures :
  1. Adverse Event [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. Change of mean BCVA score on the ETDRS visual acuity scale from baseline. [ Time Frame: 4 weeks、24 weeks、52 weeks ]
    Changes of BCVA scores on the ETDRS visual acuity chart of the study eye from baseline at 4, 24 and 52 weeks after treatment with LX109.

  2. Changes in mean eye CST from baseline at 4, 24 and 52 weeks after LX109 treatment were studied. [ Time Frame: 4 weeks、24 weeks、52 weeks ]
  3. The time after LX109 treatment to the first salvage treatment. [ Time Frame: 52 weeks ]
  4. Proportion of subjects receiving salvage treatment in the study eye at 24 weeks and 52 weeks after treatment with LX109. [ Time Frame: 24 weeks、52 weeks ]
  5. The number of times the eye received salvage treatment at 24 weeks and 52 weeks after treatment with LX109 was studied. [ Time Frame: 24 weeks、52 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 1) Informed consent must be signed before all assessments; 2) Male or female patients ≥50 years of age; 3) To investigate the presence of active CNV secondary to nAMD (occult or micromenorrhea) in the eye 4) When studying the baseline of the eye, use the ETDRS eye chart to test the BCVA of 19 to 73 letters (approximately equivalent to decimal notation) Recorded visual acuity 0.05-0.5); 5) Study eyes received at least 2 anti-VEGF treatments within 6 months. Note: For all subjects, only one eye was used as the "study eye" (i.e. the study eye receiving treatment). If both eyes of the subject meet the inclusion criteria, the eye with poor baseline vision will be selected as the study eye, or the eye with better vision may be selected for medical reasons or ethical requirements.

Exclusion Criteria:

  • 1. In the investigator's judgment, concomitant eye diseases of the study eye at screening or baseline may cause subjects to fail to respond to study therapy or confuse the interpretation of study findings. For example, diabetic retinopathy, retinal vein obstruction, retinal retinal detachment, macular hiatus (stage 3 or 4), uveitis, vitreous macular traction affecting central vision, macular anterior membrane involving macular fovea or damaging macular structure, equivalent spherical lens ≤-8.00D of the study eye, etc.

    2. To investigate the presence of subretinal hyperreflective substance (SHRM) involving the fovea except CNV lesions; 3. Central serous chorioretinopathy (CSC) was confirmed in the study eyes at any time; 4. Study retinal detachment in the eye at any time; 5. Non-study eye BCV A less than decimal recorded visual acuity 0.05(<19 ETDRS letters); 6. The presence of uncontrolled glaucoma (defined as intraocular pressure ≥25mmHg after standard treatment) in the study eye; 7. Active intraocular or periocular inflammation or infection in the study eye or non-study eye; 8. To investigate the presence of CNV or macular edema secondary to causes other than AMD; 9. In the study, the refractive medium of the eye is seriously cloudy or the pupil cannot be sufficiently dilated, affecting BCVA or causing insufficient acquisition Clear eye imaging data, such as OCT, FFA, and fundus photography, affect researchers' observation of safety and efficacy.

Eye Treatment: 10. Internal eye surgery, such as vitrectomy, cataract phacoemulsification, trabeculectomy, or other filtering surgery, was performed within 3 months prior to baseline screening or study eye screening; 11. Study eyes screened or treated with intravitreal drug injections or drug-containing intraocular implants other than anti-VEGF drugs, such as intraocular corticosteroids, within 6 months prior to baseline; 12. Research eye or systemic have received gene therapy; 13. Study eyes screened or treated with macular laser photocoagulation or photodynamic therapy (PDT) or full vision membrane laser photocoagulation within 3 months prior to baseline; 14. Study eyes were screened or underwent YAG laser posterior capsulectomy or laser trabeculectomy or laser periiridectomy within 1 month prior to baseline


Layout table for additonal information
Responsible Party: Xiaodong Sun, Assessor, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Identifier: NCT06022744    
Other Study ID Numbers: SHGH-LX109
First Posted: September 5, 2023    Key Record Dates
Last Update Posted: September 5, 2023
Last Verified: September 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No